Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
NCT ID: NCT00233948
Last Updated: 2015-04-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
29 participants
INTERVENTIONAL
2006-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This phase I/II trial is studying the side effects and best dose of nelfinavir mesylate and to see how well it works in treating patients with recurrent, metastatic, or unresectable liposarcoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
NCT03077451
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
NCT00659360
Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma
NCT00003778
Lovastatin in Treating Patients At High Risk of Melanoma
NCT00462280
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
NCT06498648
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To assess the toxicity and tolerance of nelfinavir in patients with liposarcoma.
II. To define the maximum tolerated dose (MTD) of nelfinavir when given daily as a single agent and to describe the toxicities at each does studied.
III. To evaluate the pharmacokinetics of nelfinavir. IV. To assess the response rate and progression free survival in patients with liposarcoma treated with nelfinavir.
V. To evaluate the expression and activity of certain proteins in the tumors of patients entered on this study, which may be important to the cytotoxicity of nelfinavir (SREBP-1, p21, NFkB (NFkappaB), caspase 3).
OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.
Patients receive oral nelfinavir mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I
Patients receive oral nelfinavir mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
nelfinavir mesylate
Given orally
biopsy
Correlative studies
laboratory biomarker analysis
Correlative studies
pharmacological study
Correlative studies
gene expression analysis
Correlative studies
western blotting
Correlative studies
reverse transcriptase-polymerase chain reaction
Correlative studies
immunoenzyme technique
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
nelfinavir mesylate
Given orally
biopsy
Correlative studies
laboratory biomarker analysis
Correlative studies
pharmacological study
Correlative studies
gene expression analysis
Correlative studies
western blotting
Correlative studies
reverse transcriptase-polymerase chain reaction
Correlative studies
immunoenzyme technique
Correlative studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* There is no limit to prior chemotherapy regimens; in addition, patients may have prior radiation
* All patients must have measurable disease, defined as lesions that can be accurately measured in at least one dimension (\>= 20 mm with conventional techniques or \>= 10mm with spiral CT scan); pleural effusions and ascites will not be considered measurable, but may be present in addition to the measurable lesion(s)
* ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, or 2; patients should have an expected survival of at least 3 months
* Absolute neutrophil count \>= 1,000/ul
* Platelets \>= 75000/ul
* Total bilirubin =\< 2.0 g/dl
* AST(SGOT)/ALT(SGPT) =\< 2.0X institutional upper limit of normal
* Brain metastasis is not an exclusion; however, patients are only eligible if they have had successful control of the brain tumor(s) by surgery or radiation therapy
* All prior therapy must have been completed at least 3 weeks prior to the patient's entry on this trial
* No concurrent chemotherapy, radiotherapy, immunotherapy or other investigational agents
* Women of child-bearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation; should a women become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
* Ability to understand and willingness to sign a written informed consent document
Exclusion
* Patient has had prior treatment with or is currently taking a protease inhibitor
* Patients enrolled cannot be on the following medications: cisapride, triazolam, midazolam, ergot derivatives, amiodarone, quinidine, dihydropyridine calcium antagonists (amlodipine, felodipine, isradipine, nicardipine, nifedipine, nimodipine, and nisoldipine), sildenafil, dilantin, rifampin or oral contraceptives
* Uncontrolled intercurrent illness
* Patients must have recovered from any expected toxicities of previous chemotherapy or radiation therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
City of Hope Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Warren Chow
Role: PRINCIPAL_INVESTIGATOR
City of Hope Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope Medical Center
Duarte, California, United States
South Pasadena Cancer Center
Pasadena, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2010-01263
Identifier Type: -
Identifier Source: secondary_id
CDR0000438712
Identifier Type: REGISTRY
Identifier Source: secondary_id
FDA R01FD003006-03
Identifier Type: OTHER
Identifier Source: secondary_id
04090
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.